Candel Therapeutics, Inc.

NASDAQ:CADL

Biotechnology

Healthcare
$5.32 +0.56%

+$0.05 today

Market cap
$417.33M
Beta
-0.48
P/E (TTM)
-9.2
EPS (TTM)
-$0.87
52W Low $4.35High $9.57

Volume 1.39M

Average 1.82M

CADL Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Candel Therapeutics, Inc.NASDAQ: CADL

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $1.45M rose 362.4% year over year, ahead of the +8.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 12.6% from the prior quarter. Over 3 fiscal years it compounded at +18.3% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +362.4% holds above the trailing-twelve-month pace of +8.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.45M+12.6% QoQ
Last fiscal yearDec 2025
$3.82M-28.1% YoY
LTMMar 2026
$4.96M+8.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+362.4%——
1 year-28.1%——
3-year CAGR+18.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
3.82M USD
Year-over-year change
-28.1%
4-year CAGR
+6.5%

Stock-Based Compensation vs competitors

How CADL compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +8.1% is the 4th highest of 10, against a peer median of -13.7%.
  • Over three fiscal years its annual growth of +18.3% compares with a peer median of -10.5%.
CADL Competitors
Stock-Based Compensation for CADL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$49.18M USD+10.5%+43.7%22.6%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$46.65M USD-42.2%-9.8%12.3%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥26.02M CNY+1.1%-74.4%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$25.38M USD+66.4%——
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M USD-55.6%-11.3%8.0%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$6.81M USD-13.7%-16.3%3.0%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$5.86M USD-50.8%-13.8%—
GNLXGenelux CorporationLTM Mar 2026$5.84M USD+8.8%+34.5%72950.0%
CADLCandel Therapeutics, Inc.LTM Mar 2026$4.96M USD+8.1%+18.3%—
IMMXImmix Biopharma, Inc.LTM Mar 2026$2.15M USD-27.0%+57.6%—
Peer median (excluding CADL) —-13.7%-10.5%12.3%

Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(36.12M)(18.79M)(37.94M)(55.18M)(38.18M)
Depreciation & Amortization232K778K1.28M990K845K
Deferred Income Tax11.51M0000
Stock-Based Compensation2.96M2.31M3.09M5.31M3.82M
Change in Working Capital(876K)71K(378K)346K2.19M
Accounts Receivables00000
Inventory00000
Accounts Payables669K(1.21M)45K(185K)802K
Other Working Capital(1.55M)1.28M(378K)531K1.39M
Other Non-Cash Items76K(15.78M)(301K)21.51M(6.98M)
Operating Cash Flow(22.22M)(31.42M)(34.24M)(27.02M)(38.31M)
Capital Expenditures(1.84M)(1.3M)(457K)(16K)(587K)
Acquisitions (Net)000027K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00177K00
Investing Cash Flow(1.84M)(1.3M)(280K)(16K)(560K)
Debt Repayment019.91M0(9.17M)36.21M
Common Stock Issued71.34M00101.76M19.89M
Common Stock Repurchased00(121K)00
Dividends Paid00000
Other Financing Activities465K64K01.69M0
Financing Cash Flow71.8M19.97M(121K)94.28M56.1M
Effect of Forex Changes00000
Net Change in Cash47.75M(12.74M)(34.65M)67.24M17.23M
Free Cash Flow(24.05M)(32.72M)(34.7M)(27.04M)(38.9M)

Candel Therapeutics, Inc.

NASDAQ:CADL

Intrinsic Alpha fair value

Locked

Current Price

$5.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.